Share PriceThe company presently has the capacity to produce 26500 kg annually, which equates to $159,000,00 annually, and $39,750,000 quarterly, that's not counting oil, Lesotho or Malta, last week one on one meetings, and yesterday's news
Once they announce the approval of the final rooms, it will double the above noted. Everybody else has ridden the biological asset gravy train, except for a few, the above noted is a concrete compilation of what this company can produce at the moment or the near future.
Q3 might not reflect the potential, but Q4 "should" place this company as a top tier. With a decent Q3 it should attract positive traction from the market, if not, I'm not sure what will.
This stock should be at a healthy $2.50 to $3.00 dollar range, but everyone knows the status. I'll keep buying low and selling high until I see independent growth, if it ever happens, and without a RS, I will definetely increase my position, and enter as long. IMO